Generated by AI
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders. The company's lead molecule, azetukalner, is a novel potent selective Kv7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression. Xenon's pipeline also includes early-stage potassium and sodium channel modulators, with Kv7 and Nav1.7 programs in Phase 1 development for pain management. The company addresses areas of high unmet medical need in rare central nervous system conditions and other neurological disorders. Headquartered in Burnaby, British Columbia, with additional offices in Boston, Massachusetts, Xenon operates as a clinical-stage biopharmaceutical company committed to improving the lives of patients living with complex neurological conditions.
Website200-3650 Gilmore Way
Burnaby, BC, V5G 4W8
Canada
The latest articles about XENE.
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were a
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects.
Summary of Oct 1's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Summary of Mar 11's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Investors talking about XENE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.